1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Guangzhou Pharmaceuticals Corporation - Strategic SWOT Analysis Review

Guangzhou Pharmaceuticals Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Guangzhou Pharmaceuticals Corporation (GPC), formerly Guangzhou Medicine Company, is a pharmaceutical company. The company undertakes the distribution, wholesale, retail, import and export of western and Chinese pharmaceutical products and medical apparatus. Its products portfolio includes chemical reagent, chemical medicines, medical raw materials, healthcare products and glass apparatus. The company also conducts research and development of natural medicine and biological medicine. The company offers distribution services to over 4000 health care institutions, 1800 drug stores, and over 2900 retailers nation-wide. GPC is the joint venture between Guangzhou Pharmaceutical Holdings Limited and Alliance Boots Holdings Limited. GPC is headquartered in Guangzhou, China.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Guangzhou Pharmaceuticals Corporation - Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 3
Section 1 - About the Company 4
Guangzhou Pharmaceuticals Corporation - Key Facts 4
Guangzhou Pharmaceuticals Corporation - Key Employees 5
Guangzhou Pharmaceuticals Corporation - Major Products and Services 6
Guangzhou Pharmaceuticals Corporation - History 7
Guangzhou Pharmaceuticals Corporation - Company Statement 8
Guangzhou Pharmaceuticals Corporation - Locations And Subsidiaries 9
Head Office 9
Other Locations and Subsidiaries 9
Section 2 - Company Analysis 10
Guangzhou Pharmaceuticals Corporation - Business Description 10
Guangzhou Pharmaceuticals Corporation - Corporate Strategy 11
Guangzhou Pharmaceuticals Corporation - SWOT Analysis 12
SWOT Analysis - Overview 12
Guangzhou Pharmaceuticals Corporation - Strengths 12
Strength - Leading Market Position 12
Strength - Integrated Business Model 12
Guangzhou Pharmaceuticals Corporation - Weaknesses 13
Weakness - Hepatitis B Vaccines 13
Guangzhou Pharmaceuticals Corporation - Opportunities 14
Opportunity - Market Potential: Chinese Pharmaceutical Market 14
Opportunity - Growing Aged Population in China 14
Guangzhou Pharmaceuticals Corporation - Threats 15
Threat - Competitive Pressures 15
Threat - Increasing Counterfeit Products 15
Threat - Government Regulations 15
Guangzhou Pharmaceuticals Corporation - Key Competitors 16
Section 3 - Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Guangzhou Pharmaceuticals Corporation, Key Facts 4
Guangzhou Pharmaceuticals Corporation, Key Employees 5
Guangzhou Pharmaceuticals Corporation, Major Products and Services 6
Guangzhou Pharmaceuticals Corporation, History 7
Guangzhou Pharmaceuticals Corporation, Subsidiaries 9
Guangzhou Pharmaceuticals Corporation, Key Competitors 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.